Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Trius Therapeutics

Sort by

Possible Impact of Merck Acqusition of Cubist on the Trius CVR

Monday, December 8, 2014 · 5:19 pm

Read More

Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)

Wednesday, July 31, 2013 · 1:48 pm

Read More

Trius: Topline Data of Second Phase III Trial of Tedizolid is Eminent (TSRX, $6.76)

Monday, March 18, 2013 · 8:52 am

Read More

Trius: Why Last Friday’s Equity Offering is good for the Stock (TSRX, $4.90)

Monday, January 21, 2013 · 12:03 pm

Read More

Trius Therapeutics: In an About Face, Congress is Helping Biotech Companies That Are Developing Antibiotics (TSRX, $5.54)

Monday, January 14, 2013 · 8:30 am

Read More

Settlement Between Pfizer and Teva on Generic Zyvox is a Significant Positive for Trius Therapeutics

Monday, October 29, 2012 · 10:43 am

Read More

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

Wednesday, August 22, 2012 · 11:35 am

Read More

Trius Therapeutics’ Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)

Wednesday, May 30, 2012 · 1:45 pm

Read More

There are 8 reports on file.

« Back to Company Reports Index